Merus BV Total Liabilities
Merus BV total liabilities. Based on the latest financial reports, Merus BV (MRUS) has total liabilities worth $110.36 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MRUS asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Merus BV (2012–2024)
Total liabilities of Merus BV from 2012 to 2024. This chart illustrates how Merus BV's total liabilities have evolved over time, based on quarterly financial data. Explore Merus BV long-term investment intensity to see how much of total assets are deployed in long-term investments.
Merus BV Competitors by Total Liabilities
The table below lists competitors of Merus BV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Huali Industrial Group Company Limited
SHE:300979
|
China | CN¥8.10 Billion |
|
Yealink Network Technology Corp Ltd
SHE:300628
|
China | CN¥992.51 Million |
|
Stora Enso Oyj R
HE:STERV
|
Finland | €8.01 Billion |
|
Huadong Medicine Co Ltd
SHE:000963
|
China | CN¥15.43 Billion |
|
FormFactor Inc
NASDAQ:FORM
|
USA | $231.12 Million |
|
Hellenic Telecommunications Organization S.A
AT:HTO
|
Greece | €3.07 Billion |
|
Leader Harmonious Drive Systems Co Ltd
SHG:688017
|
China | CN¥471.27 Million |
|
Apar Industries Limited
NSE:APARINDS
|
India | Rs83.18 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Merus BV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Merus BV asset portfolio.
Liquidity & Leverage Metrics
Merus BV Total Liabilities Ratios Explained
Merus BV total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Merus BV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Merus BV (2012–2024)
The table below shows the annual total liabilities of Merus BV from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $134.77 Million | +35.92% |
| 2023-12-31 | $99.15 Million | -23.43% |
| 2022-12-31 | $129.49 Million | -7.77% |
| 2021-12-31 | $140.40 Million | +8.88% |
| 2020-12-31 | $128.95 Million | -2.36% |
| 2019-12-31 | $132.08 Million | -8.83% |
| 2018-12-31 | $144.87 Million | -18.91% |
| 2017-12-31 | $178.65 Million | +343.77% |
| 2016-12-31 | $40.26 Million | +411.99% |
| 2015-12-31 | $7.86 Million | -8.91% |
| 2014-12-31 | $8.63 Million | +31.28% |
| 2013-12-31 | $6.58 Million | +97.98% |
| 2012-12-31 | $3.32 Million | -- |
About Merus BV
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the… Read more